Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market

Fineline Cube Jul 24, 2026
Company Drug

Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL

Fineline Cube Jul 24, 2026
Company Drug

Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech

Fineline Cube Apr 17, 2024

GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has...

Company

J&J’s Medical Technology Sector Rises 6.3% YOY Despite China’s VBP Impact

Fineline Cube Apr 17, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has reported its financial results for the first quarter...

Policy / Regulatory

China Unveils 2024 Plan to Combat Fraud in Medical Insurance Funds

Fineline Cube Apr 17, 2024

The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court,...

Policy / Regulatory

Chinese Authorities Launch Special Plan to Rectify Medical Insurance Fraud and Non-Compliance

Fineline Cube Apr 17, 2024

The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court,...

Drug Policy / Regulatory

China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...

Company Drug

AstraZeneca’s Imfinzi Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer Trial

Fineline Cube Apr 17, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year...

Medical Device Policy / Regulatory

China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...

Company Deals

Beijing Airdoc Leads RMB 500 Million Joint Venture to Invest in AI-Powered Healthcare

Fineline Cube Apr 17, 2024

Beijing Airdoc Technology Co., Ltd., a leading artificial intelligence (AI)-powered ophthalmology device company, has announced...

Company Drug

Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment

Fineline Cube Apr 17, 2024

Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of...

Company Drug

China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment

Fineline Cube Apr 17, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...

Company

Roche China’s Talent and Culture Vice President Chen Yanli Departs for New Opportunities

Fineline Cube Apr 16, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the departure of Chen Yanli, who...

Company Drug

Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor

Fineline Cube Apr 16, 2024

Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...

Company Drug

Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers

Fineline Cube Apr 16, 2024

Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a...

Company Drug

Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial

Fineline Cube Apr 16, 2024

Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial...

Company Drug

Novartis’s Fabhalta Shows Promise in Phase III IgA Nephropathy Trial

Fineline Cube Apr 16, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III...

Policy / Regulatory

EU Set to Investigate China’s Medical Device Procurement Practices Amid Fairness Concerns

Fineline Cube Apr 16, 2024

The European Union (EU) is reportedly gearing up to launch an investigation into medical device...

Company Deals

Ningbo Menovo Partners with University of Michigan to Develop GLP-1 Delivery System

Fineline Cube Apr 16, 2024

Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538), a China-based company, has announced a strategic partnership...

Company Deals Digital

Vazyme Partners with Yufang Medical to Boost Alzheimer’s Blood Test Sales Online

Fineline Cube Apr 16, 2024

Vazyme Biotech Co., Ltd (SHA: 688105), based in China, has entered into a strategic partnership...

Company Drug

Keymed Biosciences Achieves First Dosing in Global Phase III Trial for Claudin 18.2 Targeting ADC

Fineline Cube Apr 15, 2024

Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced the completion...

Company Deals

89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China

Fineline Cube Apr 15, 2024

U.S. biotechnology company 89bio (NASDAQ: ETNB) has secured the services of China-based Contract Development and...

Posts pagination

1 … 407 408 409 … 699

Recent updates

  • Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market
  • Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth
  • Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL
  • Hengrui Pharmaceuticals Secures NMPA First-Line Approval for Camrelizumab-Famitinib Combo in PD-L1-Positive Cervical Cancer
  • Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market

Company

Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth

Company Drug

Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL

Company Drug

Hengrui Pharmaceuticals Secures NMPA First-Line Approval for Camrelizumab-Famitinib Combo in PD-L1-Positive Cervical Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.